Introduction {#s1}
============

*Salmonella enterica* serovar Typhi (*S*. Typhi) is a human-restricted pathogen that causes typhoid fever and constitutes a major global health threat. The burden of *S*. Typhi infection is an estimated 26.9 million cases of typhoid fever annually resulting in \~217000 deaths worldwide ([@CIT0001]). Following ingestion by the oral route, *S*. Typhi infects and invades the host 'M' cells and epithelial cells and subsequently translocates to the submucosa where it encounters intestinal lymphoid tissues, before entering draining mesenteric lymph nodes, and disseminating to the liver, spleen and other secondary lymphoid tissues, resulting in systemic illness ([@CIT0004]). The most serious complication of typhoid fever is intestinal perforation which occurs mainly at the terminal ileum (TI) (in \~78% of perforation cases) suggesting that it is the favored intestinal active invasion site for *S*. Typhi ([@CIT0005], [@CIT0006]). Only very limited information is available regarding the generation of CD4^+^ T cells to *S*. Typhi in the human intestinal mucosa ([@CIT0007], [@CIT0008]). Recently, we have reported that oral Ty21a immunization elicits CD8^+^ T memory (T~M~) *S*. Typhi-specific responses in human TI specimens which differs in some key aspects from their systemic counterparts ([@CIT0009]). To our knowledge, there are no data on the induction of CD4^+^ T~M~ responses to *S.* Typhi in the TI mucosa following wild-type (wt) *S*. Typhi infection or immunization with the live attenuated oral vaccine Ty21a (Ty21a). Given that the gastrointestinal tract is a major reservoir of CD4^+^ T~M~ cells, understanding the host mucosal immune responses against *S*. Typhi and other enteric pathogens at their preferred site of natural infection is required to provide novel insights for the development of oral vaccines.

Two licensed typhoid vaccines, namely the oral live attenuated Ty21a and the parenteral Vi polysaccharide vaccine, are available in the USA for use in humans ([@CIT0004]) but they both have their limitations. The licensed attenuated Ty21a typhoid vaccine is typically administered in four spaced doses and confers a moderate level of long-lived protection (60--80%, 5--7 years) ([@CIT0004], [@CIT0010]). Hence, there is a need to develop effective new vaccines that will provide durable, long-lasting protection. We and others have extensively studied the induction of humoral and cell-mediated immunity (CMI) responses in peripheral blood mononuclear cells (PBMC) obtained from healthy volunteers following immunization with four doses of Ty21a ([@CIT0012]). These studies showed that live oral *S*. Typhi vaccines induced both CD4^+^ and CD8^+^ T-cell responses, including interferon (IFN)γ, cytotoxic T cells (CTL), proliferation and multifunctional (MF) antigen-specific cytokine-producing cells ([@CIT0012], [@CIT0015], [@CIT0017]), which might play a key role in long-term immunity. We have also reported that Ty21a elicits *S*. Typhi-specific CD4^+^ T-cell responses in PBMC by various CD4^+^ T~M~ cell subsets, including T central/memory (T~CM~), T effector/memory (T~EM~) and RA^+^ T~EM~ (T~EMRA~) ([@CIT0020], [@CIT0021]). These responses were predominantly in the T~EM~ and T~EMRA~ subsets with a low magnitude of responses observed in CD4^+^ T~CM~ subsets ([@CIT0012], [@CIT0021], [@CIT0022]). Furthermore, *S.* Typhi-specific MF cells were increased in CD4^+^ T~EM~ and T~EMRA~ subsets post-vaccination predominantly producing IFNγ and/or TNFα, while IL-2, MIP1β, IL-17A and CD107a expression (a marker associated with cytotoxicity) were observed in a small proportion of MF. In addition, it appears that CD4^+^ T- and CD8^+^ T-cell responses against *S*. Typhi depend on the nature of the stimulant. For example, CD4^+^ cells were more susceptible to respond to *S*. Typhi soluble antigens than *S*. Typhi-infected targets ([@CIT0014], [@CIT0023]). The function of CD4^+^ T cells in protection against typhoid fever in humans is still not fully understood. *Salmonella* Typhi-specific CD4^+^ T-cell responses have been detected in individuals with typhoid fever ([@CIT0024], [@CIT0025]) and very recently, using a human infection model with wt *S*. Typhi, clonotypes of CD4^+^ T cells recognizing distinct immunodominant antigens were identified ([@CIT0026]). Furthermore, using genome-wide association studies, it was also shown that the expression of specific major histocompatibility complex class II alleles confers resistance to typhoid fever ([@CIT0027]). Taken together, these data suggest that CD4^+^ T cells might play a protective function in the control of *S*. Typhi in humans. However, all of these detailed CMI responses were evaluated in peripheral blood; CD4^+^ T~M~ responses in the human TI have never been directly evaluated. Therefore, we hypothesized that *S*. Typhi-specific responses by various CD4^+^ T~M~ subsets elicited in the TI following Ty21a immunization would differ in magnitude and characteristics to their systemic counterparts. In this study, we have characterized TI-lamina propria mononuclear cells (LPMC) CD4^+^ T~M~ in Ty21a-vaccinated and unvaccinated volunteers. We then determined and compared CD4^+^ T~M~*S*. Typhi-specific responses from the two groups following stimulation with (i) autologous target cells infected with or without wt *S.* Typhi and (ii) *S*. Typhi antigens \[e.g. Ty21a homogenate, flagella (FliC)\]. Finally, we assessed these responses in depth by analyzing their multifunctionality and directly compared peripheral and mucosal CD4^+^ T~EM~ MF responses. These comparisons provide a unique insight into the similarities and differences between mucosal and peripheral immunity.

Methods {#s2}
=======

Volunteers, immunization and sample collection {#s3}
----------------------------------------------

The human experimentation guidelines of the US Department of Health and Human Services and those of the University of Maryland, Baltimore, were followed in the conduct of this study. All TI biopsies and blood specimens were collected from volunteers who participated in the University of Maryland Institutional Review Board approved protocol number HP-0005632. Volunteers undergoing routine colonoscopy who had no history of typhoid fever were recruited from the Baltimore--Washington metropolitan area and University of Maryland, Baltimore campus. Written informed consent was obtained from volunteers and all procedures were approved by the University of Maryland, Baltimore Institutional Review Board (IRB). Volunteers (demographics shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}) were assigned into two groups. The first group (*n* = 16) were immunized with four spaced doses of 2--6 × 10^9^ CFU of oral live attenuated Ty21a at an interval of 48 h between doses (Vivotif enteric-coated capsules; Crucell, Bern, Switzerland) while volunteers assigned to the second group were not vaccinated (control group) (*n* = 30) as shown in the study design ([Supplementary Figure S1](#sup3){ref-type="supplementary-material"}). Blood samples were collected at least 21 days before immunization (pre-immunization) and on colonoscopy day (day 0) together with TI biopsies using large capacity forceps ([Supplementary Figure S1](#sup3){ref-type="supplementary-material"}). PBMC were isolated immediately after blood draws by density gradient centrifugation and cryopreserved in liquid nitrogen following standard techniques ([@CIT0022]).

Isolation of LPMC from TI biopsies {#s4}
----------------------------------

TI-LPMC were freshly isolated using an optimized procedure as previously described ([@CIT0009], [@CIT0028], [@CIT0029]). Briefly, after collection of biopsies from routine colonoscopy volunteers, tissues were treated with HBSS (without CaCl~2~, MgCl~2~, MgSO~4~) (Gibco, Carlsbad, CA, USA) and EDTA (1 mM; Ambion, Grand Island, NY, USA) to remove intra-epithelial cells (IEL). LPMC were then isolated following enzymatic digestion of the biopsies with Collagenase D (100 μg ml^−1^; Roche, Indianapolis, IN, USA) and DNase I (10 μg ml^−1^; Affymetrix, Cleveland, OH, USA) and homogenization using the Bullet Blender homogenizer (Next Advance Inc., Averill, NY, USA). Cells were then washed and re-suspended in complete medium (cRPMI) \[RPMI 1640 (Gibco Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (BioWhittaker, Walkersville, MD, USA), 2 mM [[l]{.smallcaps}]{.smallcaps}-glutamine (HyClone, Logan, UT, USA), 2.5 mM sodium pyruvate (Gibco), and 10 mM HEPES (Gibco), 100 U ml^−1^ penicillin (Sigma-Aldrich, St Louis, MO, USA), 100 μg ml^−1^ streptomycin (Sigma-Aldrich), and 50 μg ml^−1^ gentamicin (Gibco)\] and counted using Kova Glastic Slides (Hycor Biomedical, CA, USA). Isolated LPMC were either stained immediately for immune phenotyping by flow cytometry or stimulated overnight with either *S*. Typhi-infected targets or soluble antigens \[Ty21a homogenate, FliC, or tetanus toxoid (TT)\] or controls before staining with a 14-color flow cytometry panel and analyzed using a customized LSR-II instrument (BD, Franklin Lakes, NJ, USA).

Target cell preparation {#s5}
-----------------------

Autologous Epstein--Barr virus (EBV)-transformed lymphoblastoid cell lines (EBV-B cells) were generated from each participant's pre-immunization PBMC, which were isolated at least 21 days before colonoscopy \[[Supplementary Figure S1](#sup3){ref-type="supplementary-material"} as previously described ([@CIT0009], [@CIT0022], [@CIT0030])\]. Briefly, EBV-B cells were obtained by incubation of PBMC with EBV-containing supernatant from the B95-8 cell line (ATCC CRL1612) and cyclosporine (0.5 μg ml^−1^; Sigma-Aldrich) at 37°C with 5% CO~2~. After transformation, EBV-B were maintained in culture in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 100 U ml^−1^ penicillin, 100 μg ml^−1^ streptomycin, 50 μg ml^−1^ gentamicin, 2 mM [l]{.smallcaps}-glutamine, 2.5 mM sodium pyruvate, 10 mM HEPES buffer and 10% heat-inactivated fetal bovine serum (R10) until used in the experiments.

Salmonella Typhi infection of target cells {#s6}
------------------------------------------

Autologous target cells (EBV-B) generated as described above were infected with wt *S.* Typhi strain (ISP1820, Vi^+^, a clinical isolate from Chile) ([@CIT0016]) at a multiplicity of infection of 7:1 as previously described ([@CIT0009], [@CIT0022], [@CIT0030]). Briefly, the targets and bacteria were incubated for 3 h at 37°C in RPMI without antibiotics, washed three times with cRMPI and incubated overnight with cRPMI containing 150 μg ml^−1^ gentamicin. *Salmonella* Typhi-infected and uninfected cells were gamma-irradiated (6000rad) for 6 min before being used as 'targets' for *ex vivo* TI-LPMC and PBMC stimulation. Cells were washed and the efficiency of the infection with *S.* Typhi-infected EBV-B was confirmed by staining with anti-*Salmonella* common structural Ag (CSA-1)-FITC (Kierkegaard and Perry, Gaithersburg, MD, USA) and analysis by flow cytometry using a customized LSR-II instrument (BD) as previously described ([@CIT0018]). The percentage of cells infected with *S.* Typhi was recorded for each experiment. Infected targets were only used if the infection was detected (CSA-1 positive) in 30--60% of viable cells.

Soluble proteins {#s7}
----------------

The Ty21a bacteria strain was obtained from the Center for Vaccine Development, University of Maryland, USA (CVD) reference stocks and was grown for 14--16 h in Luria-Bertani (LB) supplemented with 0.1% galactose as described previously ([@CIT0031]). The bacteria were then homogenized using a French press (1 cycle at 20000 psi) and the homogenate centrifuged at 17700 × *g* for 10 min. The pellet was discarded and the supernatant filtered through a 0.8 μm filter and aliquots were then kept at −20°C. The protein concentration of the Ty21a homogenate was then measured with a BCA protein kit (Fisher) and using a protein standard (BSA, Fisher). The recombinant and purified *S*. Typhi FliC was prepared as described previously ([@CIT0016]). Briefly, the FliC encoding region (residues 53--450) was subcloned from *S*. Typhi ISP1820 into pET15b. The plasmid was transformed into *Escherichia coli* Tuner (DE3) and the protein over-expressed following induction with 100 μM of isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG). The over-expressed protein was then purified by standard immobilized metal affinity column chromatography (IMAC) methods.

Stimulation of PBMC and TI-LPMC {#s8}
-------------------------------

Freshly isolated TI-LPMC and PBMC were used as effector cells as previously described ([@CIT0009], [@CIT0029]). Briefly, LPMC and PBMC (1 × 10^6^ cells per ml) effectors were co-cultured with either non-infected or *S.* Typhi-infected autologous EBV-B at an effector to stimulator cell ratio of 7:1. For soluble antigen stimulation, LPMC and PBMC effectors were induced with Ty21a homogenate (10 μg ml^−1^), FliC (10 μg ml^−1^) or TT (10 μg ml^−1^) (Sigma-Aldrich). LPMC and PBMC cultured with media only or in the presence of α-CD3/CD28 beads (Life Technologies, Grand Island, NY, USA) were used as negative and positive controls, respectively. At the time of stimulation, anti-human CD107a-FITC (5 μl; H4A3, BD, San Jose, CA, USA) was added. The CD107a antibody was used to evaluate degranulation as a measure of cytotoxicity, a mechanism essential for the killing of *S*. Typhi-infected targets by T cells ([@CIT0032]). After 2 h, 0.5 μl of Golgi Stop (Monensin, BD) and Golgi Plug (Brefeldin A, BD) were added and cultures continued overnight at 37°C in 5% CO~2~. After overnight (16--18 h) incubation, cells were harvested and prepared for flow cytometry analysis.

Surface and intracellular staining {#s9}
----------------------------------

Following stimulation, PBMC and TI-LPMC were stained for flow cytometry analysis as previously described ([@CIT0009], [@CIT0028]). Following stimulation in the presence of CD107a \[LAMP-1, a molecule expressed on the cell membrane which is widely accepted to be associated with cytotoxic T-cell activity ([@CIT0032])\], PBMC and LPMC were stained for live/dead discrimination (YEVID) (Invitrogen). Blocking of Fc receptors was performed using human immunoglobulin (3 µg ml^−1^; Sigma) and was followed by surface staining. Briefly, cells were stained with fluorescently labeled monoclonal antibodies (mAbs) directed to CD13-Pacific Orange (conjugated in-house), CD19-BV570 (HIB19, BioLegend), CD3-BV650 (OKT3, BioLegend), CD4-PE-Cy5 (RPA-T4, BD), CD8-PerCP-Cy5.5 (SK1, BD), CD45RA-biotin (HI100, BD), CD62L-APC-A780 (DREG-56, eBioscience) and integrin α~4~β~7~-A647 (ACT1; conjugated in-house) at 4°C for 30 min. Cells were washed with wash buffer and stained with streptavidin (SAV)-Qdot800 (Invitrogen) at 4°C for 30 min. Cells were then fixed and permeabilized using IC fixation and permeabilization buffers (8222/8333, eBioscience) according to the manufacturer's recommendations. This was followed by staining (4°C overnight) with mAbs directed to IL-17A-BV421 (BL168, BioLegend), IFNγ-PE-Cy7 (B27, BD), TNFα-Alexa 700 (MAb11, BD), and CD69-ECD (TP1.55.3, Beckman Coulter, Danvers, MA, USA), IL-2-BV605 (MQ1-17H12, BioLegend), and MIP1β-PE (IC271P, R&D Systems). After staining, cells were stored in 1% paraformaldehyde at 4°C until data collection. Data were collected using a customized LSR-II flow cytometer (BD) and then analyzed using the WinList version 7 (Verity Software House, Topsham, ME, USA) software package. *Salmonella* Typhi-specific responses were expressed as net percentage of positive cells (backgrounds after stimulation with uninfected cells were subtracted from values obtained with *S.* Typhi-infected stimulators). A response was considered specific if the differential in the number of positive events between experimental (*S.* Typhi-infected targets) and negative control (uninfected targets) cultures was significantly increased by *z*-tests. *Salmonella* Typhi-specific responses were expressed as net percentage of positive cells (backgrounds after stimulation with uninfected cells or with media control were subtracted from values obtained with *S.* Typhi-infected stimulators or with soluble antigens, respectively).

Surface and intracellular staining for homing markers {#s10}
-----------------------------------------------------

Freshly isolated TI-LPMC and PBMC were characterized for homing markers. Briefly, PBMC and LPMC were stained for live/dead discrimination (YEVID) (Invitrogen). Blocking of Fc receptors was performed using human immunoglobulin (3 µg ml^−1^; Sigma) and was followed by surface staining. Briefly, cells were stained with fluorescently labeled mAbs directed to CD13-Pacific Orange (conjugated in-house), CD19-BV570 (HIB19, BioLegend), CD3-BV650 (OKT3, BioLegend), CD4-V450 (RPA-T4, BD), CD8-APC-H7 (SK1, BD), CCR9-APC (FAB1791A, R&D Systems), CCR6-biotin (11A9, BD), and integrin α~4~β~7~-A647 (ACT1; conjugated in-house), Ki67-A700 (B56, BD) at 4°C for 30 min. Cells were washed with wash buffer and stained with streptavidin (SAV)-Qdot800 (Invitrogen) at 4°C for 30 min. Cells were then fixed and permeabilized using IC fixation and permeabilization buffers (8222/8333, eBioscience) according to the manufacturer's recommendations. This was followed by staining (4°C overnight) with mAbs directed to IL-17A-PerCP-Cy5.5 (N49-653, BD), IFNγ-PE-Cy7 (B27, BD), and CD69-ECD (TP1.55.3, Beckman Coulter, Danvers, MA). After staining, cells were stored in 1% paraformaldehyde at 4°C until data collection. Data were collected using a customized LSR-II flow cytometer (BD) and then analyzed using the WinList version 7 (Verity Software House) software package. This package includes the FCOM function, a subroutine that enables the analysis of the multifunctionality of the responses on a single cell basis, enabling the classification of events on the basis of combinations of selected gates. This function informs whether particular cells are single producing cells or produced two or more cytokines and/or express surface markers simultaneously.

Statistical analysis {#s11}
--------------------

Data were analyzed using the statistical software GraphPad Prism™ version 5.03 (Graphpad, San Diego, CA, USA). Statistical differences in median values between two groups were determined using Mann--Whitney tests. Wilcoxon matched pair tests were used to assess statistical differences between LPMC and PBMC paired responses. On the basis of a recent recommendation by the American Statistical Association (ASA), particularly when analyzing data sets with relatively low numbers of volunteers ([@CIT0033], [@CIT0034]), we also indicated trends in expression of markers or cytokine responses where appropriate using a *P* ≤ 0.15.

Results {#s12}
=======

Oral Ty21a immunization alters mucosal CD4^+^ T-cell frequencies {#s13}
----------------------------------------------------------------

The consequence of oral Ty21a immunization on human TI-LPMC CD4^+^ T cells in healthy volunteers has not yet been explored. To determine whether Ty21a immunization may influence (i) frequencies of CD4^+^ T cells, (ii) frequencies of CD4^+^ T~M~ subsets, (iii) expression of the activation/retention marker CD69 and (iv) expression of homing molecules on CD4^+^ T cells, we isolated TI-LPMC and PBMC from volunteers who either received four doses of Ty21a or were unvaccinated. We then characterized CD4^+^ T and T~M~ subsets from freshly isolated TI-LPMC obtained from biopsies of Ty21a-vaccinated and unvaccinated volunteers using CD62L and CD45RA markers as shown by the gating strategy depicted in [Fig. 1(A)](#F1){ref-type="fig"}. Significantly increased frequencies of total LPMC CD4^+^ T cells were observed in Ty21a vaccinees (*n* = 16) compared to those present in unvaccinated (*n* = 30) volunteers ([Fig. 1B](#F1){ref-type="fig"}). We also observed that LPMC CD4^+^ T~EM~ (CD62L^−^CD45RA^−^) cells were the predominant T~M~ population (\~70%) in TI-LPMC while CD4^+^ T~EMRA~ (CD62L^−^CD45RA^+^) (\~20%) and CD4^+^ T~CM~ (CD62L^+^CD45RA^−^) (\~10%) represented, as expected, relatively minor populations ([Fig. 1A](#F1){ref-type="fig"}). Cumulative data showed that the percentage of CD4^+^ T~EM~, T~naive~ and T~CM~ subsets was not significantly different between Ty21a-vaccinated (*n* = 16) and unvaccinated (*n* = 30) volunteers ([Fig. 1C](#F1){ref-type="fig"}). In contrast, the frequency of CD4^+^ T~EMRA~ was significantly increased following Ty21a immunization ([Fig. 1C](#F1){ref-type="fig"}). Examination of the levels of CD69 expression in LPMC CD4^+^ T~M~ (T~EM~, T~CM~, T~EMRA~) showed that almost all T~EM~ and T~EMRA~ cells, but only approximately half of T~CM~ were CD69^+^ ([Fig. 1D](#F1){ref-type="fig"}). In contrast, CD69 was expressed in a very small proportion of CD4^+^ T~M~ subsets in PBMC, indicating that the vast majority of these were, as expected, not activated ([Fig. 1D](#F1){ref-type="fig"}). Note that, largely because of the limited numbers of freshly isolated TI-LPMC available, the number of volunteers studied varies throughout in the manuscript depending on the experimental conditions being evaluated.

![Gating strategy and CD4^+^ T-cell subset frequencies in TI-LPMC isolated from Ty21a-vaccinated and non-vaccinated volunteers. (A) Freshly isolated TI-LPMC and blood (PBMC) obtained from a Ty21a-vaccinated individual were characterized for memory CD4^+^ T (CD4^+^ T~M~) cell subsets using CD62L and CD45RA markers on gated CD4^+^ T cells as shown. (B) Frequencies of CD4^+^ T cells were measured and compared between TI-LPMC obtained from Ty21a-vaccinated (*n* = 16; red symbols) and unvaccinated volunteers (*n* = 30; black symbols). (C) Comparison of the frequencies of CD4^+^ T~M~ subsets \[T~CM~ (CD62L^+^CD45RA^−^), T~EM~ (CD62L^−^CD45RA^−^), T~EMRA~ (CD62L^−^CD45RA^+^) and T~naive~ (CD62L^+^CD45RA^+^)\] in TI-LPMC obtained from Ty21a-vaccinated (*n* = 16; red symbols) and unvaccinated (*n* = 30; black symbols) volunteers. (D) The frequency of CD4^+^ T~M~ subsets (T~EM~, T~CM~ and T~EMRA~) obtained from TI-LPMC (top panel) and PBMC (bottom panel) co-expressing the activation marker CD69 was determined using flow cytometry. The percentages of CD69 expression are denoted above the corresponding gating boxes in each cytogram. Significant differences between Ty21a-vaccinated and unvaccinated volunteers are denoted as \**P* \< 0.05. Median values for each group are represented as horizontal black bars.](dxy07001){#F1}

Our group and others have demonstrated that significant proportions of *S*. Typhi-specific T cells generated following Ty21a immunization are primed for mucosal homing by expressing the intestine-homing molecule integrin α4β7 ([@CIT0008], [@CIT0021], [@CIT0035]). However, a comparison of the expression of homing markers between blood and TI-LPMC CD4^+^ T cells to evaluate the potential accumulation and retention of these incoming cells was not previously reported. To directly address this key issue, we determined the *ex vivo* frequencies of CD4^+^ T cells obtained concurrently from TI biopsies and their corresponding PBMC expressing the homing markers integrin α4β7, CCR9 and CCR6. Interestingly, we observed that the frequencies of CD4^+^ T cells expressing integrin α4β7 in TI-LPMC were significantly (*P* \< 0.05) lower than those in PBMC in unvaccinated volunteers ([Fig. 2A](#F2){ref-type="fig"}). Our results also show that the frequencies of CD4^+^ T cells expressing integrin α4β7 in blood (PBMC) decrease significantly (*P* \< 0.05) following Ty21a immunization ([Fig. 2A](#F2){ref-type="fig"}). However, no significant differences in the frequencies of integrin α4β7^+^ CD4^+^ T cells were detected between TI-LPMC and PBMC following Ty21a immunization. To further understand the homing patterns on TI-LPMC and PBMC CD4^+^ T cells, we evaluated the frequency of CCR9^+^ CD4^+^ T cells in volunteers in both groups. No significant differences in the frequencies of CCR9^+^ CD4^+^ T cells in blood and TI-LPMC following Ty21a immunization were noted ([Fig. 2B](#F2){ref-type="fig"}). However, we found that the frequencies of CCR9^+^ CD4^+^ T cells in LPMC showed a trend (*P* = 0.15) to be higher than their PBMC counterparts following Ty21a immunization ([Fig. 2B](#F2){ref-type="fig"}). Throughout the manuscript we indicated *P* ≤ 0.15 as a trend in expression of markers or cytokine responses on the basis of a recent recommendation by the ASA stating that the *P*-value depends on the degree of association and the sample size and thus, by itself, a *P*-value does not provide a good measure of evidence regarding a model or hypothesis ([@CIT0033], [@CIT0034]). In this study, we observed that the homing patterns and net CMI responses were markedly increased in some individuals, but as a group did not reach statistical significance, likely because of the relatively limited number of participants evaluated. Thus, we indicated trends when appropriate.

We next determined the frequencies of integrin α4β7^+^ CCR9^+^ CD4^+^ T cells in LPMC and PBMC in both groups of volunteers. No differences were observed in the frequencies of integrin α4β7^+^ CCR9^+^ CD4^+^ T cells between LPMC and PBMC in unvaccinated volunteers ([Fig. 2C](#F2){ref-type="fig"}). Moreover, the frequencies of integrin α4β7^+^ CCR9^+^ CD4^+^ T cells showed a trend (*P* = 0.15) to be lower in PBMC following Ty21a immunization ([Fig. 2C](#F2){ref-type="fig"}). In contrast, following Ty21a immunization we found significant increases (*P* \< 0.05) in integrin α4β7^+^ CCR9^+^ CD4^+^ T cells in TI-LPMC following Ty21a immunization ([Fig. 2C](#F2){ref-type="fig"}). Furthermore, we observed that following Ty21a immunization, the frequencies of integrin α4β7^+^ CCR9^+^ CD4^+^ T cells in TI-LPMC were significantly higher than those in PBMC ([Fig. 2C](#F2){ref-type="fig"}). Finally, we also characterized the expression of the homing marker CCR6 on CD4^+^ T cells in PBMC and LPMC obtained from both groups. No significant differences were observed in the frequencies of either LPMC or PBMC CCR6^+^ CD4^+^ T cells following Ty21a immunization. These data suggest that CD4^+^ T cells co-expressing integrin α4β7 and CCR9 may accumulate in the local TI mucosa following Ty21a immunization.

![*Ex vivo* mucosal and systemic homing phenotypes of CD4^+^ T cells following Ty21a oral vaccination. *Ex vivo* percentages of (A) integrin α4β7^+^, (B) CCR9^+^ and (C) integrin α4β7^+^ CCR9^+^ were evaluated in LPMC and PBMC CD4^+^ T cells isolated from TI biopsies and blood of Ty21a-vaccinated (red symbols; *n* = 14) and unvaccinated (black symbols; *n* = 6) volunteers using flow cytometry. Significant differences between TI-LPMC and PBMC in vaccinated and unvaccinated volunteers are denoted as \**P* \< 0.05 and \*\**P* \< 0.005. *P*-value for trends was also denoted. Median values for each group are represented as horizontal black bars.](dxy07002){#F2}

Activation of TI-LPMC CD4^+^ T cells {#s14}
------------------------------------

Most of our knowledge of CD4^+^ T responses elicited by *S*. Typhi infection or Ty21a immunization in humans is based solely on data derived from blood ([@CIT0008], [@CIT0012], [@CIT0013]). Virtually, no information is available on TI CD4^+^ T immune responses following wt *S*. Typhi infection or immunization with the Ty21a vaccine. In addition, the observation that oral Ty21a immunization significantly increases CD4^+^ T~M~ subsets (especially T~EMRA~) ([Fig. 1](#F1){ref-type="fig"}) suggests that TI CD4^+^ T cells might respond differently in magnitude and characteristics following stimulation with *S*. Typhi-infected targets. Furthermore, we hypothesized that Ty21a immunization might also influence the baseline responses or the capacity to respond to stimulation.

To address this hypothesis, we first evaluated whether *S.* Typhi-specific mucosal responses were due to baseline responses or the capacity of T~M~ to be activated following Ty21a immunization. Thus, we assessed the levels of CD4^+^ T~EM~ cytokine-producing cells and their cytotoxic potential following an overnight culture either alone (unstimulated) or following stimulation with α-CD3/CD28 beads. Cumulative data show that neither the background levels (LPMC alone) nor their activation with α-CD3/CD28 beads were significantly different between LPMC isolated from Ty21a-vaccinated (*n* = 16) and unvaccinated (*n* = 30) individuals ([Supplementary Figure S2A](#sup4){ref-type="supplementary-material"} and [B](#sup4){ref-type="supplementary-material"}). These results indicate that *ex vivo* LPMC CD4^+^ T cells did not exhibit intrinsic differences between the Ty21a-vaccinated and unvaccinated groups in background and non-specific stimulatory characteristics.

TI-LPMC CD4^+^ T~M~ subsets have unique S. Typhi-specific response profiles {#s15}
---------------------------------------------------------------------------

Next, we determined the ability of LPMC CD4^+^ T~M~ cell subsets obtained from Ty21a-vaccinated (*n* = 15) and unvaccinated (*n* = 20) volunteers to be activated following co-culture with autologous *S*. Typhi-infected or uninfected EBV-B cells by assessing their cytokines/cytotoxic responses following stimulation. Responses of representative subjects are presented in [Fig. 3](#F3){ref-type="fig"}. Following stimulation with *S*. Typhi-infected EBV-B, we observed in Ty21a vaccinees substantial net increases (% of *S.* Typhi-infected EBV-B responses − % of uninfected EBV-B responses) in the frequencies of CD4^+^ T~EM~ cells producing cytokines/chemokines (e.g. INFγ, IL-2, IL-17A and MIP1β) ([Fig. 3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}). Interestingly, the levels of individual cytokines varied following oral Ty21a immunization. Since LPMC CD4^+^ T~EM~ is the predominant memory subset in the TI, representing over 70% of total CD4^+^ T cells, we first assessed their *S*. Typhi-specific response profile ([Fig. 4A](#F4){ref-type="fig"}). Cumulative data of *S.* Typhi-specific responses were expressed as net percentages of T~EM~ positive cells. Interestingly, LPMC CD4^+^ T~EM~ producing IFNγ and IL-17A show trends to exhibit higher levels (*P* = 0.15 and 0.12, respectively) in Ty21a-vaccinated than in unvaccinated volunteers ([Fig. 4A](#F4){ref-type="fig"}). We next assessed *S.* Typhi-specific responses by TI-LPMC CD4^+^ T~CM~ and T~EMRA~ subsets. Remarkably, we observed significantly (*P* \< 0.05) higher frequencies of CD4^+^ T~CM~ producing cytokines (IFNγ and MIP1β) in LPMC obtained from Ty21a-vaccinated than in unvaccinated volunteers ([Fig. 4B](#F4){ref-type="fig"}). No significant differences in CD4^+^ T~CM~ TNFα, IL-2, and IL-17A-producing cells and CD107a-expressing cells were detected between Ty21a-vaccinated and unvaccinated volunteers ([Fig. 4B](#F4){ref-type="fig"}). A similar assessment performed in CD4^+^ T~EMRA~ revealed that this cell subset exhibited trends (*P* = 0.15) to show higher frequencies of IL-2-producing cells in LPMC obtained from Ty21a vaccinees than in their unvaccinated counterparts ([Fig. 4C](#F4){ref-type="fig"}).

![*Salmonella* Typhi-specific responses by LPMC CD4^+^ T cells isolated from the TI of a Ty21a-vaccinated and an unvaccinated representative volunteer. Using a 14-color flow cytometry panel we studied the induction of cytokine/chemokine production (IFNγ, TNFα, IL-2, IL-17A and MIP1β) and up-regulation of CD107a expression in CD69^+^ CD4^+^ T~EM~ cells obtained from (A) Ty21a-vaccinated and (B) unvaccinated representative volunteers following an overnight stimulation with non-infected or *S*. Typhi-infected autologous EBV-B cells at 37°C, 5% CO~2~. Anti (α)-CD3/CD28 beads (1 μl) and unstimulated cells were used as a positive and negative controls, respectively, in both volunteers. The percentages of positive cells in the gated regions are shown above their corresponding black boxes.](dxy07003){#F3}

![Effect of oral Ty21a immunization on TI-LPMC CD4^+^ T~M~ (T~EM~, T~CM~ and T~EMRA~) *Salmonella* Typhi-specific responses in healthy adults. The net percentages of *S.* Typhi-specific responses (IFNγ, TNFα, IL-2, IL-17A, and MIP1β production and CD107a expression) in (A) CD69^+^ CD4^+^ T~EM~, (B) CD69^+^ CD4^+^ T~CM~ and (C) CD69^+^ CD4^+^ T~EMRA~ subsets were compared between Ty21a-vaccinated (*n* = 15; red symbols) and unvaccinated volunteers (*n* = 20; black symbols) following stimulation of LPMC with autologous *S*. Typhi-infected and uninfected EBV-B. The net percentages were calculated as % responses in *S.* Typhi EBV-B stimulated cultures − % responses in uninfected EBV stimulated cultures. Significant differences (\**P* \< 0.05) and *P*-values for trends are indicated. Horizontal black bars represent median values.](dxy07004){#F4}

Multifunctional TI-LPMC CD4^+^ T~EM~ responses following oral Ty21a immunization {#s16}
--------------------------------------------------------------------------------

Our group has previously shown that peripheral blood CD4^+^ T cells respond to *S.* Typhi by secreting single or multiple cytokines simultaneously ([@CIT0012]). However, it is unknown whether TI *S*. Typhi-specific CD4^+^ T-cell responses exhibit multifunctionality, i.e. the ability to express more than one function (e.g. IFNγ) concomitantly. Thus, we next investigated the multifunctionality of LPMC *S.* Typhi-specific CD4^+^ T~EM~ responses in Ty21a-vaccinated and unvaccinated volunteers. Using WinList's FCOM function, TI-LPMC CD4^+^ T~EM~ responses were analyzed for multiple cytokines/chemokines (IFNγ, TNFα, IL-2, IL-17A and MIP1β) and/or CD107a expression (64 possible combinations) and characterized *S*. Typhi-specific responding cells as either single cytokine producers/CD107a expressors (S) or multifunctional (sum of double, triple, quadruple, quintuple or sextuple cytokine producers/CD107a expressors) (MF). First, we analyzed LPMC CD4^+^ T~EM~ responses associated with expression of CD107a, a cytotoxic marker ([@CIT0032]) ([Fig. 5A](#F5){ref-type="fig"}). Interestingly, in unvaccinated volunteers, responses had a tendency to be mostly CD107a^+^ CD4^+^ T~EM~ MF rather than CD107a^+^ CD4^+^ T~EM~ S ([Fig. 5A](#F5){ref-type="fig"}). However, no significant differences were observed between the levels of CD107a^+^ CD4^+^ T~EM~ S and MF cells following Ty21a immunization ([Fig. 5A](#F5){ref-type="fig"}).

Next, we examined the IFNγ responses for multifunctionality in Ty21a vaccinees and controls. Similar to the CD107a response, IFNγ responses were mostly MF in both volunteer groups but the levels of IFNγ^+^ CD4^+^ T~EM~ MF in Ty21a-vaccinated volunteers displayed a trend (*P* \< 0.13) to show higher frequencies than in unvaccinated volunteers ([Fig. 5B](#F5){ref-type="fig"}). Similar observations were made for IL-2 ([Fig. 5E](#F5){ref-type="fig"}) and MIP1β ([Fig. 5F](#F5){ref-type="fig"}), where the frequencies of IL-2^+^ and MIP1β^+^ CD4^+^ T~EM~ MF were significantly (*P* \< 0.05) higher in Ty21a vaccinees than in unvaccinated volunteers ([Fig. 5E](#F5){ref-type="fig"} and [F](#F5){ref-type="fig"}). In contrast, CD4^+^ T~EM~ TNFα^+^ responses were significantly higher as single (S) effectors following Ty21a immunization ([Fig. 5C](#F5){ref-type="fig"}). Remarkably, the responses associated with IL-17A production showed significant increases in *S.* Typhi-specific IL-17A^+^ MF and S in Ty21a-vaccinated than in unvaccinated volunteers ([Fig. 5D](#F5){ref-type="fig"}).

![Single and multifunctional net *Salmonella* Typhi-specific LPMC CD69^+^ CD4^+^ T~EM~ cells following oral Ty21a immunization. Following stimulation with autologous *S*. Typhi-infected and uninfected EBV-B targets and using the FCOM function of WinList, net *S*. Typhi-specific CD4^+^ T~EM~ responses were segregated into single positive effectors (S; producing only one cytokine or expressing just CD107a) and multifunctional (MF; simultaneously producing two, three, four or five cytokines and/or expressing CD107a). Comparison of TI-LPMC CD4^+^ T~EM~*S*. Typhi-specific responses as measured by (A) CD107a^+^, (B) INFγ^+^, (C) TNFα^+^, (D) IL-17A^+^, (E) IL-2^+^ and (F) MIP1β^+^ MF and S were examined in Ty21a-vaccinated (*n* = 15; red symbols) and unvaccinated volunteers (*n* = 20; black symbols) with significant differences shown (\**P* \< 0.05; \*\**P* \< 0.005). Horizontal black bars represent median values.](dxy07005){#F5}

In addition, we analyzed individual IL-17A-associated MF subsets and observed significantly higher percentages of responders in LPMC CD69^+^ CD4^+^ T~EM~ double (IL-2^+^ IL-17A^+^) (*P* \< 0.05), and quadruple (CD107a^+^ IL-2^+^ IL-17A^+^ MIP1β^+^) (*P* \< 0.0005) positive subsets following Ty21a immunization ([Supplementary Figure S3A](#sup5){ref-type="supplementary-material"}). We also analyzed individual CD107a-associated responses and found significantly higher level of quadruple (CD107a^+^ IL-2^+^ IL-17A^+^ MIP1β^+^) (*P* \< 0.0005) following Ty21a immunization ([Supplementary Figure S3B](#sup5){ref-type="supplementary-material"}).

Multifunctional TI-LPMC CD4^+^-T~EM~ responses following stimulation with soluble antigens {#s17}
------------------------------------------------------------------------------------------

Our group and others have observed that CMI against *S*. Typhi mediated by CD4^+^ T cells appears to depend on the nature of the stimulant ([@CIT0012]). For example, CD4^+^ T cells seem more prone to respond to *S*. Typhi soluble antigens than to infected targets ([@CIT0023]). We therefore examined whether LPMC CD4^+^ T~EM~ obtained from Ty21a-vaccinated and unvaccinated volunteers will respond differently following stimulation with *S.* Typhi soluble antigens (Ty21a homogenate or FliC) or to an unrelated antigen, TT. Using the FCOM function of WinList, we analyzed and stratified the data into S and MF effectors as described above. First, we analyzed LPMC CD4^+^ T~EM~ responses associated with expression of CD107a, a cytotoxic marker ([@CIT0032]) ([Fig. 6A](#F6){ref-type="fig"}). Interestingly, stimulation of LPMC CD4^+^ T~EM~ with Ty21a homogenate (10 μg ml^−1^) resulted in significant (*P* \< 0.05) expression of CD107a^+^ S in Ty21a-vaccinated than in unvaccinated volunteers ([Fig. 6A](#F6){ref-type="fig"}). A similar trend (*P* = 0.15) to show increases in the expression of CD107a^+^ S in LPMC CD4^+^ T~EM~ obtained from Ty21a-vaccinated than unvaccinated volunteers was noted following stimulation with FliC but not with TT ([Fig. 6A](#F6){ref-type="fig"}). Next, we examined the IL-17A responses for multifunctionality in Ty21a vaccinees and controls following stimulation with soluble antigens. In contrast to the CD107a responses, IL-17A responses were mostly MF in both groups of volunteers, but the levels of IL-17A^+^ CD4^+^ T~EM~ MF in Ty21a-vaccinated volunteers were significantly higher than in unvaccinated volunteers following stimulation with the Ty21a homogenate, but not with FliC or TT ([Fig. 6B](#F6){ref-type="fig"}). Similar observations were made for MIP1β ([Fig. 6C](#F6){ref-type="fig"}), where the frequencies of MIP1β^+^ CD4^+^ T~EM~ MF were significantly (*P* \< 0.05) higher in Ty21a vaccinees than in unvaccinated volunteers following stimulation with Ty21a homogenate, but not with FliC or TT ([Fig. 6C](#F6){ref-type="fig"}). In addition, we examined IFNγ, TNFα and IL-2 multifunctional responses following stimulation with soluble antigens. We observed significant increase in only CD69^+^ CD4^+^ T~EM~ IFNγ^+^ MF ([Supplementary Figure S4A](#sup6){ref-type="supplementary-material"}) obtained from Ty21a-vaccinated than in unvaccinated volunteers following stimulation with Ty21a homogenate but not with FliC or TT. Of note, no significant differences were observed in the levels of IL-2^+^ and TNFα^+^ CD4^+^ T~EM~ S and MF cells between Ty21a vaccinees and unvaccinated volunteers following stimulation with soluble antigens ([Supplementary Figure S4B](#sup6){ref-type="supplementary-material"} and [C](#sup6){ref-type="supplementary-material"}).

![Single and multifunctional *Salmonella* Typhi-specific LPMC CD69^+^ CD4^+^ T~EM~ responses to soluble antigens following oral Ty21a immunization. LPMC CD4^+^ T~EM~ were stimulated with a Ty21a homogenate (10 μg ml^−1^), FliC (10 μg ml^−1^) or TT (10 μg ml^−1^) and the net *S*. Typhi-specific CD4^+^ T~EM~ responses were calculated using the FCOM function of WinList segregating them into single positive effectors (S; producing only one cytokine or expressing just CD107a) and multifunctional (MF; simultaneously producing two, three, four or five cytokines and/or expressing CD107a). Comparison of TI-LPMC CD4^+^ T~EM~*S*. Typhi-specific responses as measured by (A) CD107a^+^, (B) IL-17A^+^ and (C) MIP1β^+^ MF and S were evaluated in Ty21a-vaccinated (red symbols) and unvaccinated volunteers (black symbols) with significant differences (\**P* \< 0.05) and *P*-value for trends shown. Horizontal black bars represent median values.](dxy07006){#F6}

Mucosal S. Typhi-specific CD4^+^ T~M~ subsets (T~EM~, T~CM~, T~EMRA~) responses are different from their systemic counterparts {#s18}
------------------------------------------------------------------------------------------------------------------------------

Recent findings have indicated that the immune responses at the site of infection are distinct from those in peripheral blood ([@CIT0028], [@CIT0029], [@CIT0036], [@CIT0037]). We have previously reported that TI CD8^+^ T~M~ cells respond differently than their systemic counterparts ([@CIT0009]). Based on these observations, we hypothesized that the specific immune responses elicited in the TI for *S*. Typhi CD4^+^ T~M~ would differ in magnitude and characteristics from their blood counterparts. To directly address this hypothesis, we sampled simultaneously blood and TI biopsies from each individual and used the exact stimulation protocol (same infected and uninfected EBV-B cells) to determine LPMC and PBMC CD4^+^ T~M~*S.* Typhi-specific responses. Mucosal and systemic net *S*. Typhi-specific CD69^+^ CD4^+^ T~M~ subset (T~EM~, T~CM~ and T~EMRA~) responses were compared in Ty21a-vaccinated and in unvaccinated volunteers ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). In unvaccinated individuals, LPMC CD69^+^ CD4^+^ T~EM~ showed trends to exhibit higher expression of CD107a and produced higher levels of IL-2 than their blood counterparts ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). Following Ty21a immunization, LPMC CD69^+^ CD4^+^ T~EM~ exhibited trends (*P* \< 0.1) to produce higher levels of IL-17A and to express higher levels of CD107a than their PBMC counterparts ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). Interestingly, LPMC CD69^+^ CD4^+^ T~CM~ produced significantly more IL-17A (*P* \< 0.05) and expressed significantly (*P* \< 0.005) higher frequencies of CD107a than their blood counterparts in unvaccinated volunteers ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). In contrast, following Ty21a vaccination, LPMC CD69^+^ CD4^+^ T~CM~ exhibited a trend to produce higher levels of IFNγ and MIP1β and expressed significantly more CD107a (*P* \< 0.005) than their PBMC counterparts ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}). Finally, we compared the responses of LPMC and PBMC CD69^+^ CD4^+^ T~EMRA~ in unvaccinated and Ty21a-vaccinated individuals. We observed no significant differences in cytokine/chemokine production (IFNγ, TNFα, IL-17A, IL-2 and MIP1β) between LPMC and PBMC but significantly higher expression of CD107a (*P* \< 0.05) in LPMC than PBMC in both Ty21a-vaccinated and unvaccinated volunteers ([Supplementary Table S2](#sup2){ref-type="supplementary-material"}).

Mucosal S. Typhi-specific multifunctional CD4^+^ T~EM~ responses are different from their systemic counterparts {#s19}
---------------------------------------------------------------------------------------------------------------

We have showed above (Result section showing differences between LPMC and PBMC CD4^+^ T~M~*S*. Typhi responses) that TI CD69^+^ CD4^+^ T~EM~ cells obtained from unvaccinated and Ty21a vaccinees exhibited trends (*P* \< 0.1) toward exhibiting higher levels of IL-17A or IL-2 production and cytotoxic potential (CD107a) than their corresponding blood counterparts. In addition, we have observed that CD4^+^ T~EM~ is the predominant T~M~ subset in the TI mucosa. Thus, we deemed it important to further stratify these responses into those exhibiting a single function and those that were multifunctional. We hypothesized that CD4^+^ T~EM~ responses will differ between the two tissues in terms of quality and quantity. Hence, we analyzed the differences in CD4^+^ T~EM~ responses between LPMC and PBMC by detailing their multifunctionality. Using the multifunctionality strategy described above, we stratified net *S.* Typhi-specific responses into multifunctional (MF) or single (S) responses for both LPMC and PBMC in Ty21a-vaccinated and unvaccinated volunteers. Interestingly, the frequencies of CD4^+^ CD107a^+^ T~EM~ MF were significantly higher (*P* \< 0.05) in LPMC than in PBMC in both Ty21a-vaccinated and unvaccinated volunteers ([Fig. 7A](#F7){ref-type="fig"}). Of note, no significant differences in CD4^+^ CD107a^+^ T~EM~ S were observed between LPMC and PBMC in unvaccinated or following Ty21a immunization ([Fig. 7A](#F7){ref-type="fig"}). Thus, the magnitude of CD107a responses in LPMC CD4^+^ T~EM~ is different from PBMC. In contrast, the frequencies of CD4^+^ T~EM~ IFNγ^+^ (S or MF) were similar between TI-LPMC and PBMC obtained from unvaccinated volunteers ([Fig. 7B](#F7){ref-type="fig"}), while in Ty21a-vaccinated volunteers, significantly higher frequencies of CD4^+^ T~EM~ IFNγ^+^ MF were observed in LPMC than in PBMC ([Fig. 7B](#F7){ref-type="fig"}). In contrast, no differences were noted in CD4^+^ T~EM~ IFNγ^+^ S between LPMC and PBMC following Ty21a immunization ([Fig. 7B](#F7){ref-type="fig"}). A similar analysis was performed for *S.* Typhi-specific TNFα ([Fig. 7C](#F7){ref-type="fig"}) and IL-2 ([Fig. 7E](#F7){ref-type="fig"}) associated responses whereby no significant differences were noted in CD69^+^ CD4^+^ T~EM~ TNFα^+^ and IL-2^+^ MF and S between LPMC and PBMC in unvaccinated volunteers. However, following Ty21a immunization, a significant increase in CD69^+^ CD4^+^ T~EM~ TNFα^+^ (*P* \< 0.0005) ([Fig. 7C](#F7){ref-type="fig"}) and IL-2^+^ MF (*P* \< 0.005) ([Fig. 7E](#F7){ref-type="fig"}) was observed in LPMC compared to PBMC. Interestingly, for IL-17A responses, we observed that the frequencies of CD4^+^ T~EM~ IL-17A^+^ MF, but not S exhibited a trend (*P* = 0.11) to show higher responses in LPMC than in PBMC obtained from unvaccinated volunteers ([Fig. 7D](#F7){ref-type="fig"}). However, following Ty21a immunization, we found that both CD4^+^ T~EM~ IL-17A^+^ MF (*P* \< 0.005) and CD4^+^ T~EM~ IL-17A^+^ S (*P* = 0.1) were higher in LPMC compared to PBMC ([Fig. 7D](#F7){ref-type="fig"}). Thus, these results suggest that IL-17A responses in LPMC CD4^+^ T~EM~ differ from their PBMC counterparts in both magnitude and characteristics. Remarkably, in unvaccinated volunteers, the frequencies of CD4^+^ T~EM~ MIP1β^+^ MF (*P* = 0.1) and S (*P* = 0.06) showed trends to exhibit higher responses in LPMC than in PBMC ([Fig. 7F](#F7){ref-type="fig"}). However, following Ty21a immunization, we observed that significantly (*P* \< 0.0005) higher frequencies of CD4^+^ T~EM~ MIP1β^+^ MF were present in LPMC than PBMC ([Fig. 7F](#F7){ref-type="fig"}). No significant differences were noted in CD4^+^ T~EM~ MIP1β^+^ S following Ty21a vaccination ([Fig. 7F](#F7){ref-type="fig"}). These data suggest that CD4^+^ T~M~ responses at the TI mucosa are different from peripheral blood.

![Mucosal and systemic single and multifunctional *Salmonella* Typhi-specific CD69^+^ CD4^+^ T~EM~ responses following oral Ty21a immunization. TI-LPMC and PBMC were stimulated in parallel with autologous *S*. Typhi-infected and uninfected EBV-B overnight. Net *S*. Typhi-specific CD4^+^ T~EM~ multifunctional (MF; simultaneously producing two, three, four or five cytokines and/or expressing CD107a) and single positive (S; producing only one cytokine or expressing just CD107a) effectors were evaluated and compared between TI-LPMC and PBMC obtained from Ty21a-vaccinated (*n* = 15; red symbols) and unvaccinated volunteers (*n* = 20; black symbols). Responses measured by (A) CD107a^+^, (B) INFγ^+^, (C) TNFα^+^, (D) IL-17A^+^, (E) IL-2^+^ and (F) MIP1β^+^ are shown. Significant differences (\**P* \< 0.05; \*\**P* \< 0.005; \*\*\**P* \< 0.0005) and *P*-value for trends are indicated. Horizontal black bars represent median values.](dxy07007){#F7}

Discussion {#s20}
==========

CD4 T cells are crucial for the generation of vaccine-mediated immune responses which are likely to contribute to effective protective immunity against a multitude of pathogens. Furthermore, it is becoming clear that the immune responses in tissues differ from those in peripheral blood. Thus, it is imperative to evaluate T-cell-mediated (T-CMI) responses at the site of infection as part of vaccine development efforts. Here, we determined the effect of oral immunization with the attenuated oral typhoid vaccine Ty21a on CD4^+^ T~M~*S.* Typhi-specific responses in human TI-LPMC and PBMC. We showed that the effect of oral Ty21a immunization at the terminal ileum mucosa, the preferred site of infection for S. Typhi ([@CIT0005], [@CIT0038]) resulted in: (i) increased of CD4+ T-cell frequencies, (ii) influence the homing and accumulation of effectors and (iii) induces LPMC S. Typhi-responsive CD4+ T multifunctional (IL-17A, IL-2 and/or MIP1β) cells. Specifically, we observed that all major CD4^+^ T~M~ subsets (T~EM~, T~CM~ and T~EMRA~) are activated and appear to display distinct response profiles (T~EM~: trends to show increases in IFNγ and IL-17A production; T~CM~: significant increases in IFNγ and MIP1β production; T~EMRA~: trends to show increases in IL-2 production) in the TI mucosa following Ty21a immunization. Moreover, we demonstrated that TI-LPMC CD4^+^ T~M~*S*. Typhi-specific responses were multifunctional and different to those present in their systemic counterparts following Ty21a immunization. Taken together, these results contribute important novel information to the immune responses elicited following oral Ty21a immunization in TI mucosal responses in humans, which could have significant implications in future vaccine design and development.

Herein we provide the first direct evidence that oral Ty21a immunization elicits *S.* Typhi-specific LPMC CD4^+^ T multifunctional responses (IL-17A, IL-2 and/or MIP1β) in the TI. Interestingly, it was recently shown that oral Ty21a immunization generates multifunctional *S*. Typhi-responsive CD4^+^ T cells obtained from human duodenum biopsies but not from CD4^+^ T cells isolated from human colon biopsies ([@CIT0007]). Taken together, these data indicate that human intestinal responses are compartmentalized following oral Ty21a immunization. However, the magnitude and characteristics of *S*. Typhi-responsive CD4^+^ T cells appear to be different between duodenum and TI. Based on the frequencies of CD4^+^ T cells producing IFNγ, TNFα and IL-2 from both studies, TI CD4^+^ T responses appear to be lower in magnitude, but exhibited marked differences in their characteristics (e.g. S versus MF), when compared to those in the duodenum. However, it is unclear whether this and other inconsistencies are the result of differences in the antigens used to stimulate cells isolated from duodenal and TI biopsies. For example, it is possible that the use of Ty21a-killed bacteria, instead of the *S.* Typhi-infected autologous targets or Ty21a homogenate employed in the present study, favored the detection of CD4^+^ responses in the duodenum ([@CIT0007]). Of importance, following immunization we observed only trends in the induction of CD4^+^ T~EM~ subsets while we observed significant responses when analyzing the data for S and MF CD4^+^ T~EM~ effectors. This suggests that studying heterogeneous CD4^+^ T populations may not reveal the 'true' impact of immunization because of the 'averaging effect' inherent to the analyses of whole populations/subsets composed of responding and non-responding cells, each with their own characteristics. Thus, when analyzing immunity elicited by vaccination it is essential to focus on the fine granularity (e.g. *S.* Typhi-specific T~M~ subsets, whether the responses are S versus MF, which combinations of cytokines are produced following antigenic stimulation) to better characterize the responses and properly study differences between immune compartments. We here demonstrated that oral Ty21a immunization elicited local TI-LPMC CD4^+^ T cells that respond specifically to *S*. Typhi antigens through effector mechanisms (e.g. IL-17) that might be well suited for protection against intracellular pathogens.

Remarkably, we also noted that several of the unvaccinated volunteers showed relatively high level of baseline *S*. Typhi-specific CD4^+^ T responses. These differences in baseline responses could be due to cross-reactive in memory responses elicited by previous exposure to other *Salmonella* serovars ([@CIT0039]) or other *Enterobacteriaceae*, including those present in the normal gut microbiota ([@CIT0012], [@CIT0042]). The importance of the gut microbiota in modulating host immune responses to pathogens or to vaccination has been demonstrated previously ([@CIT0042]). Furthermore, genetic determinants like HLA molecules can also be important in defining the variation in immune responses. For example, the presence of the *HLA*-*DRB1\*04:05* allele was recently associated with protection against *S.* Typhi ([@CIT0027]). Interestingly, higher baseline levels of multifunctional *S.* Typhi-specific CD4^+^ T cells might well play a role in the protection of disease similar to what was observed with baseline CD8^+^ T cells in an oral challenge model with wt *S.* Typhi in humans ([@CIT0045], [@CIT0046]).

Our observations that oral Ty21a elicited higher frequencies of TI CD4^+^ T cells mainly in the T~EMRA~ subsets are intriguing. However, increases in the frequencies of these subsets were not necessarily accompanied by increases in their functional properties. For example, increases in the frequencies of T~EMRA~ did not result in increases in the cytokines they produced (except for IL-2 which exhibited a trend to show higher levels in Ty21a vaccinees). However, the observation that T~EMRA~ increased in number suggests that they are induced by Ty21a immunization and might play a role in protection.

We speculate that the most likely scenario is that Ty21a immunization induces localized inflammation, thereby triggering proliferation and differentiation of *S.* Typhi-specific CD4^+^ T~M~ and enhanced recruitment of effector cells to the site of infection. We hypothesize that the increased frequencies in the TI-LPMC CD4^+^ T~EMRA~ subset may be a result of recruitment of these T~EMRA~ cells from circulation or that CD4^+^ T~EM~ were elicited to proliferate and differentiate into T~EMRA~ in the local microenvironment. Remarkably, the patterns of homing markers (integrin α4β7 and CCR9) displayed simultaneously in isolated TI-LPMC and PBMC CD4^+^ T cells were distinct. We observed that integrin α4β7^+^ CD4^+^ T cells are significantly decreased in PBMC but not in LPMC following Ty21a immunization. Furthermore, CCR9^+^ CD4^+^ or integrin α4β7^+^ CCR9^+^ CD4^+^ LPMC T cells were increased in the TI, suggesting that *S.* Typhi-specific cells are recruited and accumulate in the mucosa. These observations argue in favor of integrin α4β7-driven recruitment and retention of specific CD4^+^ T~M~ in the mucosa, likely associated with a potential down-regulation of integrin α4β7^+^ CD4^+^ T cells in the local microenvironment ([@CIT0028], [@CIT0047]). Our observations together with data supporting the induction of *S*. Typhi-specific responses in the duodenum but not the colon following Ty21a immunization suggest that integrin α4β7^+^/α4β7^+^ CCR9^+^ and CCR9^+^ CD4^+^ T cells may play a crucial role in anti-*S*. Typhi immunity in the human small intestine.

We have demonstrated that all major CD4^+^ T~M~ subsets (T~EM~, T~CM~ and T~EMRA~) are elicited in the TI mucosa following Ty21a immunization. However, each CD4^+^ T~M~ subset appears to display unique response profiles (e.g. trends by CD4^+^ T~EM~ to exhibit increases in the production of IFNγ and IL-17A) and CD4^+^ T~EM~ MF cells predominate, as we have previously shown in peripheral blood ([@CIT0020]). Of note, the frequencies of LPMC CD4^+^ T~CM~ and T~EMRA~ (10--30% and 20--40%, respectively) are significantly lower than CD4^+^ T~EM~ (45--80%) in the TI mucosa. Taken together, these data suggest that LPMC CD4^+^ T~EM~ and T~CM~ (by producing increased levels of IFNγ and MIP1β) may contribute to the induction of T~h~1 and T~h~17 effectors while CD4^+^ T~EMRA~ which exhibited a trend to produce higher levels of IL-2 may be required for expansion of antigen-specific CD4^+^ T-cell populations and maintenance of regulatory T cells (T~reg~) following Ty21a immunization or challenge with wt *S.* Typhi ([@CIT0048]).

Generation of CD4^+^ T~M~*S*. Typhi-specific responses is likely to be dependent on the type of antigenic stimulation, as shown by the exposure of LPMC CD4^+^ T~EM~ to either soluble antigens (e.g. Ty21a homogenate or flagella) or autologous infected targets (e.g. *S*. Typhi-EBV-B) in our studies. We noted that CD4^+^ T~EM~*S*. Typhi-specific IFNγ MF, TNFα S, MIP1β MF and IL-17A MF were similarly elicited by stimulation with either targets or soluble antigens following Ty21a immunization. In contrast, the potential to be cytotoxic (CD107 expression; which showed significant increases with soluble antigen) and production of IL-2 (which exhibited significant increases with infected targets) seems to be dependent on the type of stimulation. Therefore, CD4^+^ T~EM~ responses against *S*. Typhi seem to display a core response in terms of T~h~1 (IFNγ, TNFα and/or MIP1β) and T~h~17 (IL-17A) but may be dependent on the type of stimulation for other effector responses (IL-2 and cytotoxic).

A recent study using a human infection model with wt *S.* Typhi has identified important components of the CD4^+^ T-cell responses selectively targeting *S.* Typhi ([@CIT0026]). This study suggests that only the bacterial antigens expressed in the infected tissues are targeted during the CD4^+^ T-cell responses to *Salmonella*. Thus, it appears that antigens present in the tissues during *Salmonella* infection dictate the antigen-specific repertoire of CD4^+^ T cells consisting of cross-reactive and serovar-specific T-cell clonotypes. Interestingly, these authors also showed that the identified circulating CD4^+^ effector cells (CD4^+^CD38^+^CCR7^−^) expressed gut homing markers CD49d and integrin β7 ([@CIT0026]), suggesting that these cells migrate to the site of infection in the intestine. These data are concordant with our observations that circulating CD4^+^ effectors are recruited from blood and accumulate in the gut mucosa. These cells, together with resident CD4^+^ T cells, might play an important role in protection against *S.* Typhi infection. Future studies are required to examine whether wt infection or immunization influences the antigen-specific repertoire as well as the frequency of *Salmonella*-responsive tissue-resident CD4^+^ T cells.

*Salmonella* Typhi-specific multifunctional (MF) T cells have been observed in blood in response to various vaccines, including Ty21a ([@CIT0012], [@CIT0013], [@CIT0015]). Of importance, the induction of MF cells has been associated with controlling a variety of viral and bacterial pathogens ([@CIT0049], [@CIT0050]). We now show that CD4^+^ T~EM~ MF cells are induced in the TI mucosa following Ty21a immunization. For all cytokines/chemokine and cytotoxic responses evaluated (IFNγ, TNFα, IL-17A, IL-2, MIP1β and/or CD107a), MF CD4^+^ T~EM~ cells are dominant in the TI mucosa and are of higher magnitude than their PBMC counterparts regardless of Ty21a immunization. These observations argue that the TI is a major reservoir of *S*. Typhi-responsive multifunctional CD4^+^ T~M~ cells, and that the frequencies of these cells increase further following Ty21a vaccination. In addition, these data confirm and extend our previous findings that some volunteers respond specifically to *S*. Typhi before Ty21a vaccination ([@CIT0009], [@CIT0045], [@CIT0046]). Finally, another notable observation is that following Ty21a immunization, LPMC CD4^+^ T~EM~ S responses (TNFα and IL-17A) are preferentially induced in the local microenvironment as opposed to the responses observed in peripheral blood. These and other differences noted in the present studies suggest that TI-LPMC CD4^+^ T~EM~ exhibit unique patterns of *S*. Typhi-specific responses compared to their systemic counterparts. This is an important observation as most human studies depend on data acquired from the systemic compartment and largely assumed that these peripheral blood responses impact directly those present in the mucosal compartment ([@CIT0009], [@CIT0036]). Consequently, interpretation of immunological response data obtained from blood may not fully be representative of responses at the site of infection and may be different at various times following immunization. In [Fig. 8](#F8){ref-type="fig"}, we include a cartoon summarizing the multitude of responses observed in these studies, both in peripheral blood and TI.

![Cartoon depicting *Salmonella* Typhi-specific CD4^+^ T~M~ responses elicited in the TI mucosa and peripheral blood (PBMC) following Ty21a immunization in humans. Following oral immunization with the attenuated vaccine strain Ty21a, these bacteria enter the host by various mechanisms (e.g. M-cell adhesion, epithelial invasion and capture by luminal dendritic cells) and are presented by antigen-presenting cells (APC, i.e. macrophages, dendritic cells) to immune cells (i.e. CD4^+^ T~M~) in the lamina propria (LP) compartment. CD4^+^ T~M~ are subsequently activated to produce higher levels of cytokines/chemokines (IFNγ, TNFα, IL-2, IL-17A and MIP1β) and increased cytotoxicity (up-regulation of CD107a). Following Ty21a immunization each major CD4^+^ T~M~ (T~EM~, T~CM~ and T~EMRA~) subset acquires unique characteristics in the TI-LP. CD4^+^ T~EM~ responses include single producing effector cells (S) and multifunctional cells (MF). LPMC CD4^+^ T~EM~ TNFα and IL-17A responses were observed both as S and MF cells while the other responses were observed only as MF cells. The relationship between mucosal and systemic immunity focused on CD4^+^ T~EM~ responses is also depicted in this cartoon. Following Ty21a immunization, PBMC CD4^+^ T~EM~ are modulated to produce cytokine responses (IFNγ, IL-17A and IL-2). These responses are almost exclusively as MF cells rather than single producing (S) cells. Of importance, the magnitude of PBMC CD4^+^ T~EM~ responses is significantly lower than that of LPMC CD4^+^ T~EM~ as denoted by the green arrows in the LPMC compartment (↑). These results suggest that only CD4^+^ T~EM~ IL-17A^+^ S effectors elicited by Ty21a immunization might have the capacity to shuttle between the TI mucosa and peripheral blood or that these cells become MF once they are in the gut mucosa. CD4^+^ T~EM~ in the TI can be composed of various subsets including tissue-resident memory T cells (T~RM~) and other CD4^+^ T-cell subsets. Additionally, CD4^+^ T~EM~ MF represent 64 different combinations of effector subtypes defined by the expression of CD107a, IFNγ, IL-17A, TNFα, IL-2 and/or MIP1β, including doublet to sextuplet subtypes. This adds another layer of complexity in defining effector responses. This is illustrated in the figure by showing, for example, CD4^+^ T~EM~ MF quadruplets (subtype CD107a^+^, IL-17A^+^, IL-2^+^ and MIP1β^+^) which exhibited significantly higher responses in Ty21a-vaccinated than unvaccinated volunteers. Significantly higher responses in Ty21a vaccinees than in unvaccinated volunteers are denoted with red asterisks (\*). Trends toward Ty21a vaccinees exhibiting higher responses than unvaccinated volunteers are denoted with black arrows (↑). Significantly higher responses in TI-LPMC compared to PBMC are denoted with green arrows (↑). Trends toward TI-LPMC showing higher responses than PBMC are denoted with red arrows (↑).](dxy07008){#F8}

In conclusion, we have demonstrated that oral Ty21a immunization elicits *S*. Typhi-specific CD4^+^ T~M~ responses in the TI mucosa with distinct effector functions and characteristics that are unique, overlapping only partially with those observed in the systemic compartment ([Fig. 8](#F8){ref-type="fig"}). Additionally, our data offer major insights into the *S*. Typhi-specific CD4^+^ T~M~ responses elicited in the TI mucosa and suggest that these responses are the result of local immunomodulatory mechanisms capable of influencing T cell activation, expansion and differentiation, resulting in unique phenotypes and perhaps specificities than those in the systemic compartment.
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